cGAS在系统性硬化症相关间质性肺病中表达增强并促进炎症性肌成纤维细胞活化
该研究探讨了环鸟苷酸-腺苷酸合成酶(cGAS)在系统性硬化症相关间质性肺病(SSc-ILD)中的作用。通过人肺组织、支气管肺泡灌洗液、培养的肺成纤维细胞、精密切割肺切片及博来霉素小鼠模型,发现cGAS通路在SSc-ILD中活化,并促进炎症性肌成纤维细胞表型,小分子cGAS抑制剂可减轻该表型。
要点
- SSc-ILD肺组织和肺泡灌洗液中cGAS、细胞因子及1型干扰素表达增加。
- cGAS通路在SSc-ILD成纤维细胞中组成性活化,正常成纤维细胞可被TGF-β1或机械刺激诱导。
- 小分子cGAS抑制剂可减轻炎症性肌成纤维细胞活化,提示靶向cGAS是潜在治疗策略。
核心结论
- cGAS信号通路参与SSc-ILD致病性炎症性肌成纤维细胞表型的形成。
- 抑制cGAS或其下游效应分子可能成为SSc-ILD的新型治疗途径。
研究设计与样本
- 研究使用人生物标本(SSc-ILD肺组织、支气管肺泡灌洗液、分离的肺成纤维细胞)、培养的成纤维细胞、精密切割肺切片以及博来霉素肺纤维化动物模型。
- 在公共SSc-ILD单细胞RNA测序数据集中评估cGAS活化。
主要发现
- SSc-ILD肺组织和支气管肺泡灌洗液中cGAS、细胞因子和1型干扰素富集。
- cGAS通路在SSc-ILD成纤维细胞中组成性活化,在正常人类肺成纤维细胞中可由转化生长因子-β1或机械刺激诱导。
- 在上述条件下及精密切割肺切片中,cGAS表达与细胞因子、1型干扰素和α-平滑肌肌动蛋白产生相平行,小分子cGAS抑制剂可减轻这些效应。
- 这些发现也在博来霉素小鼠模型中重现。
临床怎么用
- cGAS表达和活性可能作为SSc-ILD炎症性肌成纤维细胞活化的生物标志物。
- 小分子cGAS抑制剂在临床前模型中显示减轻炎症性肌成纤维细胞活化的潜力,支持进一步临床转化研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The lungs of patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) contain inflammatory myofibroblasts that arise in association with fibrotic stimuli and perturbed innate immunity. The cytosolic DNA-binding receptor cyclic GMP-AMP synthase (cGAS) is implicated in inflammation and fibrosis, but its involvement in SSc-ILD remains unknown. We examined cGAS expression, activity and therapeutic potential in SSc-ILD using human biospecimens, cultured fibroblasts, precision-cut lung slices and a well-accepted animal model. METHODS: Expression and localisation of cGAS, cytokines and type 1 interferons were evaluated in SSc‑ILD lung tissues, bronchoalveolar lavage fluid and isolated lung fibroblasts. CGAS activation was assessed in a publicly available SSc-ILD single-cell RNA-sequencing dataset. Production of cytokines, type 1 interferons and α-smooth muscle actin elicited by transforming growth factor-β1 or local substrate stiffness was measured in normal human lung fibroblasts via quantitative reverse transcription PCR, ELISA and immunofluorescence. Small molecule cGAS inhibition was tested in cultured fibroblasts, human precision-cut lung slices and the bleomycin pulmonary fibrosis model. RESULTS: SSc-ILD lung tissue and bronchoalveolar lavage fluid were enriched for cGAS, cytokines and type 1 interferons. The cGAS pathway showed constitutive activation in SSc-ILD fibroblasts and was inducible in normal human lung fibroblasts by transforming growth factor-β1 or mechanical stimuli. In these settings, and in precision-cut lung slices, cGAS expression was paralleled by the production of cytokines, type 1 interferons and α-smooth muscle actin, which was mitigated by a small molecule cGAS inhibitor. These findings were recapitulated in the bleomycin mouse model. CONCLUSION: cGAS signalling contributes to pathogenic inflammatory myofibroblast phenotypes in SSc‑ILD. Inhibiting cGAS or its downstream effectors represents a novel therapeutic approach.
引用
- Yu S, Hu B, Sun Y, et al. Cyclic GMP-AMP synthase expression is enhanced in systemic sclerosis-associated interstitial lung disease and stimulates inflammatory myofibroblast activation. Eur Respir J. 2025. PMID: 40374521. doi:10.1183/13993003.01564-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。